JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Immunocore Holdings PLC ADR

Slēgts

32.4 -0.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

32.03

Max

32.68

Galvenie mērījumi

By Trading Economics

Ienākumi

29M

5M

Pārdošana

9.8M

94M

Peļņas marža

5.35

Darbinieki

493

EBITDA

13M

-3.6M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+106.36% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

131M

1.6B

Iepriekšējā atvēršanas cena

33.04

Iepriekšējā slēgšanas cena

32.4

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 5. aug. 23:11 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

2025. g. 5. aug. 22:45 UTC

Peļņas

Australia's REA Hikes Dividend as Annual Profit Rises 23%

2025. g. 5. aug. 22:39 UTC

Peļņas

Great-West Lifeco Logs Lower 2Q Profit

2025. g. 5. aug. 21:32 UTC

Peļņas

Coupang Posts Higher 2Q Sales Due to Customer Growth

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

NFL to Take 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

2025. g. 6. aug. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

2025. g. 5. aug. 23:48 UTC

Tirgus saruna

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

2025. g. 5. aug. 23:40 UTC

Tirgus saruna

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

2025. g. 5. aug. 23:19 UTC

Tirgus saruna

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

2025. g. 5. aug. 23:03 UTC

Tirgus saruna
Peļņas

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

2025. g. 5. aug. 22:22 UTC

Peļņas

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

2025. g. 5. aug. 22:21 UTC

Peļņas

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

2025. g. 5. aug. 22:20 UTC

Peļņas

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

2025. g. 5. aug. 22:18 UTC

Peļņas

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

2025. g. 5. aug. 22:17 UTC

Peļņas

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

2025. g. 5. aug. 22:16 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

2025. g. 5. aug. 22:15 UTC

Peļņas

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

2025. g. 5. aug. 22:13 UTC

Peļņas

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

2025. g. 5. aug. 22:12 UTC

Peļņas

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

2025. g. 5. aug. 21:58 UTC

Peļņas

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025. g. 5. aug. 21:30 UTC

Peļņas

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

2025. g. 5. aug. 21:26 UTC

Peļņas

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

2025. g. 5. aug. 21:23 UTC

Peļņas

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

2025. g. 5. aug. 21:17 UTC

Peļņas

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

106.36% augšup

Prognoze 12 mēnešiem

Vidējais 67.13 USD  106.36%

Augstākais 100 USD

Zemākais 36 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.